Ontogeny of hepatic glucuronidation; Methods and results

Current Drug Metabolism

Volumn 13, Issue 6, 2012, Pages 728-743

  Krekels, Elke H J ^a,b   Danhof, Meindert ^a   Tibboel, Dick ^b   Knibbe, Catherijne A J ^a,b,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Glucuronidation; Hepatic metabolism; Maturation; Ontogeny; Pediatrics; UGT

Indexed keywords

CARBAMAZEPINE; COMPLEMENTARY DNA; EPIRUBICIN; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; HUMAN SERUM ALBUMIN; LAMOTRIGINE; MESSENGER RNA; MORPHINE; OROSOMUCOID; PARACETAMOL; PROPOFOL; SALICYLAMIDE; VALPROIC ACID; ZIDOVUDINE;

ALLOMETRY; ANTICONVULSANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BODY WEIGHT; CRIGLER NAJJAR SYNDROME; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; EXTRACORPOREAL OXYGENATION; GENE MUTATION; GENETIC VARIABILITY; GILBERT DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER BLOOD FLOW; LIVER CELL; LIVER CLEARANCE; LIVER MICROSOME; NONHUMAN; NORTHERN BLOTTING; ONTOGENY; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION;

ANIMALS; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS;

EID: 84863664786     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012800840455     Document Type: Article

References (149)

1. Gong, Q.L.; Hedner, T.; Hedner, J.; Bjorkman, R.; Nordberg, G. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur. J. Pharmacol., 1991, 193(1), 47-56.
2. Mackenzie, P.I.; Bock, K.W.; Burchell, B.; Guillemette, C.; Iku-shiro, S.; Iyanagi, T.; Miners, J.O.; Owens, I.S.; Nebert, D.W. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics, 2005, 15(10), 677-685.
3. Cubitt, H.E.; Houston, J.B.; Galetin, A. Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance. Pharm. Res., 2009, 26(5), 1073-1083.
4. Ohno, S.; Nakajin, S. Determination of mRNA expression of hu-man UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 2009, 37(1), 32-40.
5. Nakamura, A.; Nakajima, M.; Yamanaka, H.; Fujiwara, R.; Yokoi, T. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab. Dispos., 2008, 36(8), 1461-1464.
6. Tukey, R.H.; Strassburg, C.P. Human UDP-glucuronosyltrans-ferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol., 2000, 40, 581-616.
7. Bosma, P.J.; Seppen, J.; Goldhoorn, B.; Bakker, C.; Oude Elferink, R.P.; Chowdhury, J.R. Chowdhury, N.R.; Jansen, P.L. Bilirubin UDP- glucuronosyltransferase 1 is the only relevant bilirubin glucu-ronidating isoform in man. J. Biol. Chem., 1994, 269(27), 17960-17964.
8. Iyer, L.; King, C.D.; Whitington, P.F.; Green, M.D.; Roy, S.K.; Tephly, T.R.; Coffman, B.L.; Ratain, M.J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphos-phate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest., 1998, 101(4), 847-854.
9. Court, M.H.; Duan, S.X.; Von Moltke, L.L.; Greenblatt, D.J.; Pat-ten, C.J.; Miners, J.O.; Mackenzie, P.I. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J. Pharmacol. Exp. Ther., 2001, 299(3), 998-1006.
10. Uchaipichat, V.; Mackenzie, P.I.; Guo, X.H.; Gardner-Stephen, D.; Galetin, A.; Houston, J.B.: Miners, J.O. Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab. Dispos., 2004, 32(4), 413-423.
11. Kato, Y.; Ikushiro, S.; Emi, Y.; Tamaki, S.; Suzuki, H.; Sakaki, T.; Yamada, S.; Degawa, M. Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans. Drug Me-tab. Dispos., 2008, 36(1), 51-55.
12. Takekuma, Y.; Takenaka, T.; Kiyokawa, M.; Yamazaki, K.; Oka-moto, H.; Kitabatake, A.; Tsutsui, H.; Sugawara, M. Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol. J. Pharm. Pharm. Sci., 2006, 9(1), 101-112.
13. Court, M.H. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol., 2005, 400, 104-116.
14. Miyagi, S.J.; Collier, A.C. Pediatric development of glucuronida-tion: the ontogeny of hepatic UGT1A4. Drug Metab. Dispos., 2007, 35(9), 1587-1592.
15. Argikar, U.A.; Remmel, R.P. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP- glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab. Dispos., 2009, 37(1), 229-236.
16. Benedetti, M.S.; Whomsley, R.; Baltes, E.; Tonner, F. Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. Eur. J. Clin. Pharmacol., 2005, 61(12), 863-872.
17. Krishnaswamy, S.; Duan, S.X.; Von Moltke, L.L.; Greenblatt, D.J.; Court, M.H. Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab. Dispos., 2003, 31(1), 133-139.
18. Ethell, B.T.; Anderson, G.D.; Burchell, B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP- glucuronosyltransferases. Biochem. Pharmacol., 2003, 65(9), 1441-1449.
19. Chen, M.; LeDuc, B.; Kerr, S.; Howe, D.; Williams, D.A. Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol. Drug Metab. Dispos., 2010, 38(3), 368-375.
20. Mano, Y.; Usui, T.; Kamimura, H. Contribution of UDP- glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur. J. Clin. Pharmacol., 2007, 63(3), 289-296.
21. Court, M.H.; Duan, S.X.; Guillemette, C.; Journault, K.; Krishnas-wamy, S.; Von Moltke, L.L., Greenblatt, D.J. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Me-tab. Dispos., 2002, 30(11), 1257-1265.
22. Turgeon, D.; Carrier, J.S.; Levesque, E.; Hum, D.W.; Belanger, A. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology, 2001, 142(2), 778-787.
23. Coffman, B.L.; Rios, G.R.; King, C.D.; Tephly, T.R. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos., 1997, 25(1), 1-4.
24. Coffman, B.L.; King, C.D.; Rios, G.R.; Tephly, T.R. The glucuron-idation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos., 1998, 26(1), 73-77.
25. Court, M.H.; Krishnaswamy, S.; Hao, Q.; Duan, S.X.; Patten, C.J.; Von Moltke, L.L.; Greenblatt, D.J. Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab. Dispos., 2003, 31(9), 1125-1133.
26. Barbier, O.; Turgeon, D.; Girard, C.; Green, M.D.; Tephly, T.R.; Hum, D.W.; Bélanger, A. 3'-azido-3'-deoxythimidine (AZT) is glu-curonidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab. Dispos., 2000, 28(5), 497-502.
27. Staines, A.G.; Coughtrie, M.W.; Burchell, B. N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J. Pharmacol. Exp. Ther., 2004, 311(3), 1131-1137.
28. Chung, J.Y.; Cho, J.Y.; Yu, K.S.; Kim, J.R.; Lim, K.S.; Sohn, D.R.; Shin, S.G.; Jang, I.J. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin. Pharmacol. Ther., 2008, 83(4), 595-600.
29. Innocenti, F.; Iyer, L.; Ramirez, J.; Green, M.D.; Ratain, M.J. Epirubicin glucuronidation is catalyzed by human UDP-glucurono-syltransferase 2B7. Drug Metab, Dispos., 2001, 29(5), 686-692.
30. Zhou, D.; Guo, J.; Linnenbach AJ.; Booth-Genthe, C.L.; Grimm, S.W. Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine. Drug Metab. Dispos., 2010, 38(5), 863-870.
31. Jin, C.J.; Miners, J.O.; Lillywhite, K.J.; Mackenzie, P.I. cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. Biochem. Biophys. Res. Commun., 1993, 194(1), 496-503.
32. He, X.; Hesse, L.M.; Hazarika, S.; Masse, G.; Harmatz, J.S.; Greenblatt, D.J. et al. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br. J. Clin. Pharmacol., 2009, 68(5), 721-730.
33. Levesque, E.; Turgeon, D.; Carrier, J.S.; Montminy, V.; Beaulieu, M.; Belanger, A. Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry, 2001, 40(13), 3869-3881.
34. Court, M.H. Interindividual variability in hepatic drug glucuronida-tion: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab. Rev., 2010, 42(1), 202-217.
35. Congiu, M.; Mashford, M.L.; Slavin, J.L.; Desmond, P.V. UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab. Dispos., 2002, 30(2), 129-134.
36. Strassburg, C.P.; Strassburg, A.; Kneip, S.; Barut, A.; Tukey, R.H.; Rodeck, B. et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut, 2002, 50(2), 259-265.
37. Coughtrie, M.W.; Burchell, B.; Leakey, J.E.; Hume, R. The inadequacy of perinatal glucuronidation: immunoblot analysis of the developmental expression of individual UDP-glucuronosyltransferase isoenzymes in rat and human liver microsomes. Mol. Pharmacol. 1988, 34(6), 729-735.
38. Zaya, M.J.; Hines, R.N.; Stevens, J.C. Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab. Dispos., 2006, 34(12), 2097-2101.
39. Basu, N.K.; Kole, L.; Owens, I.S. Evidence for phosphorylation requirement for human bilirubin UDP-glucuronosyltransferase (UGT1A1) activity. Biochem. Biophys. Res. Commun., 2003, 303(1), 98-104.
40. Barbier, O.; Girard, C.; Breton, R.; Belanger, A.; Hum, D.W. N-glycosylation and residue 96 are involved in the functional properties of UDP-glucuronosyltransferase enzymes. Biochemistry, 2000, 39(38), 11540-11552.
41. Mackenzie, P.I. The effect of N-linked glycosylation on the substrate preferences of UDP glucuronosyltransferases. Biochem. Bio-phys. Res. Commun., 1990, 166(3), 1293-1299.
42. Ishii, Y, Takeda, S.; Yamada, H. Modulation of UDP- glucuronosyltransferase activity by protein-protein association. Drug Metab. Rev., 2010, 42(1), 140-153.
43. Castuma CE, Brenner RR. The influence of fatty acid unsaturation and physical properties of microsomal membrane phospholipids on UDP- glucuronyltransferase activity. Biochem. J., 1989; 258(3), 723-731.
44. Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO. Isoform selectivity and kinetics of morphine 3-and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab. Dispos., 2003, 31(9), 1086-1089.
45. Sorich MJ, Smith PA, McKinnon RA, Miners JO. Pharmacophore and quantitative structure activity relationship modelling of UDP- glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacoge-netics, 2002, 12(8), 635-645.
46. Miners, J.O; Smith, P.A.; Sorich, M.J.; McKinnon, R.A.; Mackenzie, P.I. Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 1-25.
47. Gebhardt, R. Metabolic zonation of the liver: regulation and implications for liver function. Pharmacol. Ther., 1992, 53(3), 275
48. Ahsew. itt, N.J.; Lechon, M.J.; Houston, J.B.; Hallifax, D.; Brown, H.S.; Maurel, P et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev., 2007, 39(1), 159-234.
49. Miners, J.O.; Knights, K.M.; Houston, J.B.; Mackenzie, P.I. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem. Pharmacol., 2006, 71(11), 1531-1539.
50. Engtrakul, J.J.; Foti, R.S.; Strelevitz, T.J.; Fisher, M.B. Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment. Drug Metab. Dispos., 2005, 33(11), 1621-1627.
51. Hengstler. J.G.; Utesch, D.; Steinberg, P.; Platt, K.L.; Diener, B, Ringel, M et al. Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab. Rev., 2000, 32(1), 81-118.
52. McGinnity, D.F.; Soars, M.G.; Urbanowicz, R.A.; Riley, R.J. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos., 2004, 32(11), 1247-1253.
53. Steinberg, P.; Fischer, T.; Kiulies, S.; Biefang, K.; Platt, K.L.; Oesch, F et al. Drug metabolizing capacity of cryopreserved human, rat, and mouse liver parenchymal cells in suspension. Drug Metab. Dispos., 1999, 27(12), 1415-1422.
54. Onishi, S.; Kawadem, N,; Itoh, S.; Isobe, K.; Sugiyama, S. Postnatal development of uridine diphosphate glucuronyltransferase activity towards bilirubin and 2-aminophenol in human liver. Biochem. J., 1979, 184(3), 705-707.
55. Kawade, N.; Onishi, S. The prenatal and postnatal development of UDP-glucuronyltransferase activity towards bilirubin and the effect of premature birth on this activity in the human liver. Biochem. J., 1981, 196(1), 257-260.
56. Leakey, J.E.; Hume, R.; Burchell, B. Development of multiple activities of UDP-glucuronyltransferase in human liver. Biochem. J., 1987, 243(3), 859-861.
57. Rollins, D.E.; von Bahr, C.; Glaumann, H.; Moldeus, P.; Rane, A. Acetaminophen: potentially toxic metabolite formed by human fetal and adult liver microsomes and isolated fetal liver cells. Science, 1979, 205(4413), 1414-1416.
58. Pacifici, G.M.; Sawe, J.; Kager, L.; Rane, A. Morphine glucuroni-dation in human fetal and adult liver. Eur. J. Clin. Pharmacol., 1982, 22(6), 553-558.
59. Mackenzie, P.I.; Gregory, P.A.; Lewinsky, R.H.; Yasmin, S.N.; Height, T.; McKinnon, R.A et al. Polymorphic variations in the expression of the chemical detoxifying UDP glucuronosyltrans-ferases. Toxicol. Appl. Pharmacol., 2005, 207(2 Suppl):77-83.
60. Kadakol, A.; Ghosh, S.S.; Sappal, B.S.; Sharma, G.; Chowdhury, JR, Chowdhury NR. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum. Mutat., 2000; 16(4), 297-306.
61. Sneitz, N.; Bakker, C.T.; de Knegt, R.J.; Halley, D.J.; Finel, M.; Bosma, P.J. Crigler-Najjar syndrome in The Netherlands: identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants. Hum. Mutat., 2010, 31(1), 52-59.
62. Udomuksorn, W.; Elliot, D.J.; Lewis, B.C.; Mackenzie, P.I.; Yoovathaworn, K.; Miners, J.O. Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuron-idation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet. Genomics, 2007, 17(12), 1017-1029.
63. Mori, A.; Maruo, Y.; Iwai, M.; Sato, H.; Takeuchi, Y. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese popula-tion and kinetics of clozapine glucuronidation. Drug Metab. Dispos., 2005, 33(5), 672-675.
64. Ehmer. U,.;Vogel, A.; Schutte, J.K.; Krone, B.; Manns, M.P.; Strassburg, C.P. Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology, 2004, 39(4), 970-977.
65. Krishnaswamy. S.; Hao, Q.; Al Rohaimi, A.; Hesse, L.M.; Von Moltke, L.L.; Greenblatt, D.J et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J. Pharmacol. Exp. Ther., 2005, 313(3), 1340-1346.
66. Takahashi, H.; Maruo, Y.; Mori, A.; Iwai, M.; Sato, H.; Takeuchi, Y. Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin. Pharmacol. Toxicol., 2008, 103(2), 131-136.
67. Bhasker, C.R.; McKinnon, W.; Stone, A.; Lo, A.C.; Kubota, T.; Ishizaki, T et al. Genetic polymorphism of UDP-glucurono-syltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics, 2000, 10(8), 679-685.
68. Holthe, M.; Klepstad, P.; Zahlsen, K.; Borchgrevink, P.C.; Hagen, L.; Dale, O et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur. J. Clin. Pharmacol., 2002, 58(5), 353-356.
69. Kwara, A.; Lartey, M.; Boamah, I.; Rezk, N.L.; Oliver-Commey, J, Kenu, E et al. Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J. Clin. Pharmacol., 2009, 49(9), 1079-1090.
70. Holthe, M.; Rakvag, T.N.; Klepstad, P.; Idle. J.R.; Kaasa, S.; Kro-kan, H.E et al. Sequence variations in the UDP-glucurono-syltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmaco-genomic, J., 2003, 3(1), 17-26.
71. Levesque, E.; Beaulieu, M.; Green, M.D.; Tephly, T.R.; Belanger, A.; Hum, D.W. Isolation and characterization of UGT2B15(Y85): a UDP- glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics, 1997, 7(4), 317-325.
72. Court, M.H.; Hao, Q.; Krishnaswamy, S.; Bekaii-Saab, T.; Al Ro-haimi, A.; Von Moltke L.L et al. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J. Pharmacol. Exp. Ther., 2004, 310(2), 656-665.
73. Chung, J.Y.; Cho J.Y.; Yu, K.S.; Kim, J.R, Jung, H.R, Lim, K.S et al. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin. Pharmacol. Ther., 2005, 77(6), 486-494.
74. Olson, K.C.; Dellinger, R.W.; Zhong, Q.; Sun, D.; Amin, S.; Spratt TE et al. Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene. Drug Metab. Dispos., 2009, 37(10), 1999-2007.
75. Girard, H.; Villeneuve, L.; Court, M.H.; Fortier, L.C.; Caron, P.; Hao, Q et al. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuroni-dation levels in the liver. Drug Metab. Dispos., 2006, 34(7), 1220-1228.
76. Barter, Z.E.; Bayliss, M.K.; Beaune, P.H.; Boobis, A.R.; Carlile, D.J.; Edwards, R.J. et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellular-ity per gram of liver. Curr. Drug Metab., 2007, 8(1), 33-45.
77. Barter, Z.E.; Chowdry, J.E.; Harlow, J.R.; Snawder, J.E.; Lip-scomb, J.C.; Rostami-Hodjegan, A. Covariation of human micro-somal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab. Dispos., 2008, 36(12), 2405-2409.
78. Johnson, T.N.; Tucker, G.T.; Tanner, M.S.; Rostami-Hodjegan, A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl., 2005, 11(12), 1481-1493.
79. Valentin, J. Basic anatomical and physiological data for use in radiological protection: reference values. ICRP Publication 89 2001.
80. Johnson, T.N.; Boussery, K.; Rowland-Yeo, K.; Tucker, G.T.; Rostami-Hodjegan, A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet., 2010, 49(3), 189-206.
81. Yang, J.; Jamei, M.; Yeo, K.R.; Rostami-Hodjegan, A.; Tucker, G.T. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab. Dispos., 2007, 35(3), 501-502.
82. Pang, K.S.; Rowland, M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm., 1977, 5(6), 625-653.
83. Alcorn, J.; McNamara, P.J. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin. Pharmacokinet., 2002, 41(12), 959-998.
84. McNamara, P.J.; Alcorn, J. Protein binding predictions in infants. AAPS PharmSci., 2002, 4(1), E4.
85. Johnson, T.N.; Rostami-Hodjegan, A.; Tucker, G.T. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet., 2006, 45(9), 931-956.
86. Pacifici, G.M.; Taddeucci-Brunelli, G.; Rane, A. Clonazepam serum protein binding during development. Clin. Pharmacol. Ther., 1984, 35(3), 354-359.
87. Benson, J.M.; Boudinot, F.D.; Pennell, A.T.; Cunningham, F.E.; DiPiro, J.T. In vitro protein binding of cefonicid and cefuroxime in adult and neonatal sera. Antimicrob. Agents Chemother., 1993, 37(6), 1343-1347.
88. Wang, Z, O'Connor, T.P.; Heshka, S.; Heymsfield, S.B. The reconstruction of Kleiber's law at the organ-tissue level. J. Nutr., 2001, 131(11), 2967-2970.
89. Lin, J.H, Yamazaki, M. Role of P-glycoprotein in pharmacokinet-ics: clinical implications. Clin. Pharmacokinet., 2003, 42(1):59-98.
90. Schuetz, E.G.; Furuya, K.N.; Schuetz, J.D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp.Ther., 1995, 275(2), 1011-1018.
91. Hallifax, D.; Foster, J.A.; Houston, J.B. Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm. Res., 2010, 27(10), 2150-2161.
92. Fagerholm, U. Prediction of human pharmacokinetics-improving microsome-based predictions of hepatic metabolic clearance. J. Pharm. Pharmacol, 2007, 59(10), 1427-1431.
93. Li, A.P. Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem. Biol. Interact., 2007, 168(1), 16-29.
94. Miles, K.K.; Stern, S.T.; Smith, P.C.; Kessler, F.K.; Ali, S.; Ritter, J.K. An investigation of human and rat liver microsomal mycophe-nolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity. Drug Me-tab. Dispos., 2005, 33(10), 1513-1520.
95. De Cock, R.F.; Piana, C.; Krekels, E.H.; Danhof, M.; Allegaert, K.; Knibbe, C.A. The role of population PK-PD modelling in paediat-ric clinical research. Eur. J. Clin. Pharmacol., 2011, 67 (Suppl 1), 5-16.
96. Sutherland, J.M. Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. AMA J. Dis. Child, 1959, 97(6), 761-767.
97. Vest, M. Insufficient glucuronide formation in the newborn and its relationship to the pathogenesis of icterus neonatorum. Arch. Dis. Child, 1958, 33(171), 473-476.
98. Miller, R.P.; Roberts, R.J.; Fischer, L.J. Acetaminophen elimination kinetics in neonates, children, and adults. Clin. Pharmacol. Ther., 1976, 19(3), 284-294.
99. Alam, S.N.; Roberts, R.J.; Fischer, L.J. Age-related differences in salicylamide and acetaminophen conjugation in man. J. Pediatr., 1977, 90(1), 130-135.
100. Levy, G.; Khanna, N.N.; Soda, D.M.; Tsuzuki, O.; Stern, L. Pharmacokinetics of acetaminophen in the human neonate: formation of acetaminophen glucuronide and sulfate in relation to plasma bilirubin concentration and D-glucaric acid excretion. Pediatrics, 1975, 55(6), 818-825.
101. Van Lingen, R.A.; Deinum, J.T.; Quak, J.M.; Kuizenga, A.J.; van Dam, J.G.; Anand. K.J. et al. Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates. Arch. Dis. Child Fetal Neonatal Ed., 1999, 80(1), F59-F63.
102. Anderson, B.J.; Woollard, G, A.; Holford, N.H. A model for size and age changes in the pharmacokinetics of paracetamol in neo-nates, infants and children. Br. J. Clin. Pharmacol., 2000, 50(2), 125-134.
103. Anderson, B.J.; Van Lingen, R.A.; Hansen, T.G.; Lin, Y.C.; Holford, N.H. Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. An-esthesiology, 2002, 96(6), 1336-1345.
104. Van der Marel, C.D.; Anderson, B.J.; Van Lingen, R.A.; Holford, N.H.; Pluim, M.A.; Jansman, F.G et al. Paracetamol and metabolite pharmacokinetics in infants. Eur. J. Clin. Pharmacol., 2003, 59(3), 243-251.
105. Allegaert, K.; Anderson, B.J.; Naulaers, G.; de Hoon, J.; Verbesselt, R.; Debeer, A et al. Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. Eur. J. Clin. Pharmacol., 2004, 60(3), 191-197.
106. Allegaert, K.; de Hoon, J.; Verbesselt, R.; Vanhole, C.; Devlieger, H.; Tibboel, D. Intra-and interindividual variability of glucuroni-dation of paracetamol during repeated administration of propacetamol in neonates. Acta Paediatr., 2005, 94(9), 1273-1279.
107. Anderson, B.J.; Pons, G.; Autret-Leca, E.; Allegaert, K.; Boccard, E. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Paediatr. Anaesth., 2005, 15(4), 282-292.
108. Allegaert, K.;Van der, Marel.; C.D.; Debeer, A.; Pluim, M.A.; Van Lingen, R.A.; Vanhole, C. et al. Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. Arch. Dis. Child Fetal Neonatal, Ed 2004, 89(1), F25-F28.
109. Center for Disease Control and Prevention. Growth charts. http://www.cdc.gov/growthcharts. (Accessed June 29, 2011).
110. Gelotte CK, Auiler JF, Lynch JM, Temple AR, Slattery JT. Disposition of acetaminophen at 4, 6, and 8 g/day for 3 days in healthy young adults. Clin Pharmacol Ther 2007; 81(6), 840-848.
111. Krekels, E.H.; van Ham, S.; Allegaert, K.; de Hoon, J.; Tibboel, D.; Danhof, M.; Knibbe, C.A. Paracetamol pharmacokinetics in term and preterm neonates. PAGE19 2010; Abstract 1749.
112. Choonara, I.; Ekbom, Y.; Lindstrom, B.; Rane, A. Morphine sul-phation in children. Br. J. Clin. Pharmacol., 1990, 30(6), 897-900.
113. Hartley, R.; Green, M.; Quinn, M.W.; Rushforth, J.A.; Levene, M.I. Development of morphine glucuronidation in premature neo-nates. Biol. Neonate, 1994, 66(1), 1-9.
114. Barrett, D.A.; Barker, D.P.; Rutter, N.; Pawula, M.; Shaw, P.N. Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. Br. J. Clin. Pharmacol., 1996, 41(6), 531-537.
115. Saarenmaa, E.; Neuvonen, P.J.; Rosenberg, P.; Fellman, V. Morphine clearance and effects in newborn infants in relation to gesta-tional age. Clin. Pharmacol. Ther., 2000, 68(2), 160-166.
116. Choonara, I.A.;McKay, P.; Hain, R.; Rane. A. Morphine metabolism in children. Br. J. Clin. Pharmacol., 1989, 28(5), 599-604.
117. McRorie, T.I.; Lynn, A.M.; Nespeca, M.K.; Opheim, K.E.; Slat-tery, J.T. The maturation of morphine clearance and metabolism. Am. J. Dis. Child, 1992, 146(8), 972-976.
118. Bouwmeester, N.J.; van den Anker, J.N.; Hop, W.C.; Anand, K.J.; Tibboel, D. Age-and therapy-related effects on morphine requirements and plasma concentrations of morphine and its metabolites in postoperative infants. Br. J. Anaesth., 2003, 90(5), 642-652.
119. Lynn, A.M.; Nespeca, M.K.; Bratton, S.L.; Shen, D.D. Intravenous morphine in postoperative infants: intermittent bolus dosing versus targeted continuous infusions. Pain, 2000, 88(1), 89-95.
120. Choonara, I.; Lawrence, A.; Michalkiewicz, A, Bowhay, A.; Rat-cliffe, J. Morphine metabolism in neonates and infants. Br. J. Clin. Pharmacol., 1992, 34(5), 434-437.
121. Bouwmeester, N.J.; Anderson, B.J.; Tibboel, D.; Holford, N.H. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br. J. Anaesth., 2004, 92(2), 208-217.
122. Anand, K.J.; Anderson, B.J.; Holford, N.H.; Hall, R.W.; Young, T.; Shephard, B et al. Morphine pharmacokinetics and pharmacody-namics in preterm and term neonates: secondary results from the NEOPAIN trial. Br. J. Anaesth., 2008, 101(5), 680-689.
123. Knibbe, C.A.; Krekels, E.H.; van den Anker, J.N.; DeJongh, J.; Santen, G.W.; van Dijk, M et al. Morphine glucuronidation in pre-term neonates, infants and children younger than 3 years. Clin. Pharmacokinet., 2009, 48(6), 371-385.
124. Boucher, F.D, Modlin, J.F.; Weller, S.; Ruff, A.; Mirochnick, M; Pelton, S et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J. Pe-diatr., 1993, 122(1), 137-144.
125. Mirochnick, M.; Capparelli, E.p; Connor, J. Pharmacokinetics of zidovudine in infants: a population analysis across studies. Clin. Pharmacol. Ther., 1999, 66(1), 16-24.
126. Capparelli, E.V.; Englund, J.A.; Connor, J.D.; Spector, S.A.; McKinney, R.E.; Palumbo, P et al. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J. Clin. Pharmacol., 2003, 43(2), 133-140.
127. Mirochnick, M.; Capparelli, E.; Dankner, W.; Sperling, R.S.; van Dyke, R.; Spector, S.A.; Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. Antimi-crob. Agents Chemother., 1998, 42(4), 808-812.
128. Capparelli, E.V.; Mirochnickm, M.; Dankner, W.M.; Blanchard, S.; Mofenson, L.; McSherry, G.D et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J. Pediatr., 2003, 142(1), 47-52.
129. Allegaert, K.; Vancraeynest, J.; Rayyan, M.; de Hoon, J.; Cossey, V.; Naulaers, G et al. Urinary propofol metabolites in early life after single intravenous bolus. Br. J. Anaesth., 2008, 101(6), 827-831.
130. Allegaert, K.; Peeters, M.Y.; Verbesselt, R.; Tibboel, D.; Naulaers, G.; de Hoon, J.N et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br. J. Anaesth., 2007, 99(6), 864-870.
131. Kataria, B.K.; Ved, S.A.; Nicodemus, H.F.; Hoy, G.R.; Lea, D.; Dubois, M.Y et al. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology, 1994, 80(1), 104-122.
132. Wang, C.; Peeters. M.Y.M.; Allegaert, K.; Tibboel, D.; Danhof, M.; Knibbe, C.A.J. Scaling clearance of propofol from preterm neonates to adults using an allometric model with a bodyweight-dependent maturational exponent. PAGE 19 2010; Abstract 1818.
133. Peeters, M.Y.; Allegaert. K.;Blusse van Oud-Alblas, H.J.; Cella, M.; Tibboel, D.; Danhof, M et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin. Pharmacokinet., 2010, 49(4), 269-275.
134. Knudsen, A. Maternal smoking and the bilirubin concentration in the first three days of life. Eur. J. Obstet. Gynecol. Reprod. Biol., 1991, 40(2), 123-127.
135. Soars, M.G.; Petullo, D.M.; Eckstein, J.A.; Kasper, S.C.; Wrighton, S.A. An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab. Dispos., 2004, 32(1), 140-148.
136. Kostrubsky, S.E.; Sinclair, J.F.; Strom, S.C.; Wood, S.; Urda, E.; Stolz, D.B et al. Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyl-transferases in cultured human hepatocytes. Toxicol. Sci., 2005, 87(1), 146-155.
137. Roka., A.; Melinda, K.T.; Vasarhelyi, B.; Machay, T.; Azzopardi, D.; Szabo, M. Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy. Pediatrics, 2008, 121(4), e844-e849.
138. Lynn, A, Nespeca MK, Bratton SL, Strauss SG, Shen DD. Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. Anesth. Analg., 1998, 86(5), 958-963.
139. Dagan, O.; Klein, J.; Bohn, D.; Barker, G.; Koren, G. Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. J. Cardiothorac. Vasc. Anesth., 1993, 7(4), 396-398.
140. Buck., M.L. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin. Pharmacokinet., 2003, 42(5), 403-417.
141. Peters. JW, Anderson BJ, Simons SH, Uges DR, Tibboel D. Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. Intensive Care Med., 2005, 31(2), 257-263.
142. Peters, J.W.; Anderson, B.J.; Simons, S.H.; Uges, D.R.; Tibboel; D. Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates. Clin. Pharmacoki-net., 2006, 45(7), 705-714.
143. Dagan, O.; Klein, J.; Bohn, D.; Koren, G. Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit. Care Med., 1994, 22(7), 1099-1101.
144. Geiduschek, J.M.; Lynn, A.M.; Bratton, S.L.; Sanders, J.C.; Levy, FH, Haberkern, C.M, et al. Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extra-corporeal membrane oxygenation. Crit. Care Med., 1997, 25(2), 360-364.
145. Levesque, E.; Delage, R.; Benoit-Biancamano, M.O.; Caron, P.; Bernard, O.; Couture, F et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic
146. Lin, Z.; Fontaine, J.; Watchko, J.F. Coexpression of gene polymorphisms involved in bilirubin production and metabolism. Pediatrics, 2008, 122(1), e156-e162.
147. Chen, G.; Giambrone, N.E. Jr.; Dluzen, D.F.; Muscat, J.E.; Berg, A.; Gallagher, C.J et al. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. Cancer Res., 2010, 70(19), 7543-7552.
148. Knibbe, C.A.; Krekels, E.H.; Danhof, M. Advances in paediatric pharmacokinetics. Expert Opin. Drug Metab. Toxicol., 2011, 7(1), 1-8.
149. Krekels, E.H.; Panoilia, E.; Neely, M.; Tibboel, D.; Capparelli, E.; Danhof, M et al. Maturation of glucuronidation; a system specific property. PAGE 20, 2011; Abstract 2062.